| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6083953 | CHEPLAPHARM | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
Mar, 2015
(9 years ago) | |
|
US6083953 (Pediatric) | CHEPLAPHARM | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
Sep, 2015
(8 years ago) | |
| US9642911 | CHEPLAPHARM | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(3 years from now) | |
| US8889109 | CHEPLAPHARM | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(3 years from now) | |
Valcyte is owned by Cheplapharm.
Valcyte contains Valganciclovir Hydrochloride.
Valcyte has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Valcyte are:
- US6083953
- US6083953*PED
Valcyte was authorised for market use on 29 March, 2001.
Valcyte is available in tablet;oral, for solution;oral dosage forms.
Valcyte can be used as prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative).
The generics of Valcyte are possible to be released after 11 December, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 23, 2018 |
| New Dosing Schedule(D-148) | Apr 23, 2018 |
| Pediatric Exclusivity(PED) | Feb 28, 2013 |
| New Dosing Schedule(D-125) | Aug 05, 2013 |
| New Indication(I-604) | Aug 28, 2012 |
Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient
Market Authorisation Date: 29 March, 2001
Treatment: Prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative)
Dosage: TABLET;ORAL; FOR SOLUTION;ORAL
VALCYTE family patents
